Drug Discovery
ByCan Pfizer’s 2025 Earnings Reignite Confidence in Its Post-COVID Portfolio and Late-Stage Pipeline?
Late January 2026 | Full-Year 2025 Earnings Preview | Big Pharma Strategy Reset Pfizer is set to report…
Will Novartis’ January 2026 Earnings Validate the Strength of Its Focused Portfolio and Late-Stage Pipeline?
January 30, 2026 | Full-Year 2025 Earnings Preview | Innovative Medicines Outlook Novartis is scheduled to report its…
Will Roche’s 2025 Earnings Reset the Narrative for 2026 Growth and Pipeline Confidence?
January 29, 2026 | Full-Year Earnings | Big Pharma Outlook Roche is set to publish its full-year 2025…
Why Is Roche Returning to China for Its Next Antibody-Drug Conjugate Bet?
January 2026 – Strategic Partnerships | China Biopharma | Oncology & ADCs Roche has extended its collaboration with…
Qure.ai Secures Landmark FDA Clearance for qXR-Detect, Cementing AI Leadership in Global Diagnostics—Brainlab Partnership Signals Agentic AI Workflow Revolution
Mumbai, India – March 4, 2026 – Qure.ai, a global leader in AI-powered radiology, today celebrated FDA clearance for…
RecovryAI’s FDA Breakthrough: Post-Op AI Agents’ 85% Complication Prediction or Wearable Hype Meets Reality?
RecovryAI snared FDA Breakthrough Device Designation on March 4, 2026, for its physician-prescribed Virtual Care Assistants—AI agents that…
